The molecular defect in the abnormal fibrinogen Dusart (Paris V) that is associated with thrombophilia was determined by sequence analysis of genomic DNA that had been amplified using the polymerase chain reaction. The propositus was heterozygous for a single base change (C-->T) in the A alpha-chain gene, resulting in the amino acid substitution A alpha 554 Arg-->Cys. Restriction analysis of the amplified DNA derived from the family members showed that his father and his two sons were also heterozygous. Electron microscopic studies on fibrin formed from purified fibrinogen Dusart demonstrated fibers that were much thinner than in normal fibrin. In contrast to the previously observed defective binding of plasminogen, the binding of thrombospondin to immobilized fibrinogen Dusart was similar to that of normal fibrinogen. Immunoblot analysis of plasma fibrinogen demonstrated that a substantial part of the fibrinogen Dusart molecules were disulfidelinked to albumin. The plasma of the affected family members also contained fibrinogenalbumin complexes. Furthermore, small amounts of high molecular weight complexes containing fibrinogen were detected in all the heterozygous individuals. These data indicate that the molecular abnormality in fibrinogen Dusart (A alpha 554 Arg-->Cys) results in defective lateral association of the fibrin fibers and disulfide-linked complex formation with albumin, and is associated with a family history of recurrent thrombosis in the affected individuals.
Introduction
Release of the fibrinopeptides FpA and FpB from fibrinogen exposes two types of polymerization sites, designated "A" and "B," in the amino-terminal portion of the fibrin molecule (1) that appear to function cooperatively in the fibrin self-assembly process (2, 3) . Complementary polymerization sites, designated "a" and "b," respectively, are located in the carboxyl-terminal regions of the molecule (1) . Fibrin assembly commences with formation ofdouble-stranded fibrils (2-6), which Receivedfor publication 17 October 1991 and in revisedform 13 October 1992. then branch to form a three-dimensional matrix, concomitant with lateral association of fibrils, that results in increased fiber thickness (7) (8) (9) . Fibril formation is predominantly due to interaction between the A and a sites (4) ; interaction between B and b sites contributes to lateral fibril association and augment thick fiber formation (4, 9) . It has recently been suggested that the carboxyl-terminal region of the Aa chain constitutes an important component of the b polymerization site in fibrinogen ( 10) .
Congenital abnormal fibrinogens not only provide tools for studying the structure-function relationship in fibrinogen, but they also offer us an opportunity to determine the relationship between the molecular defect and the clinical symptoms ofthe affected individuals. More than 240 cases of inherited dysfibrinogenemia have been reported ( 1), of which 48 are associated with clinically significant thromboembolic disease. In one such case, fibrinogen Dusart, the functional defect is related to reduced plasminogen binding ( 12) , impaired plasminogen activation by the tissue-type plasminogen activator (t-PA' [ 13 ] ), and abnormal fibrin polymerization ( 12 2).
In this paper we report the structural defect of fibrinogen Dusart (Paris V), inferred from genetic analysis using PCR ( 14) . The presence ofthe mutation in the family members and the influence on fibrin polymerization was determined. The additional cysteine created by the mutation was involved in the formation of fibrinogen-albumin complexes in plasma. Furthermore, the family history of recurrent thrombosis and the analysis of the fibrinogen gene in the family members demonstrate a convincing association between the molecular defect and the thrombophilia.
Methods
Coagulation studies on plasma. Blood was collected by venepuncture and anticoagulated with 0.1 vol of 0.13 M trisodium citrate. Platelet poor plasma was prepared by centrifuging citrated blood at 2,000 g for 15 min at 150C. Thrombin and Reptilase clotting times were performed as described before ( 15). Fibrinogen concentration was determined functionally according to Clauss ( 16) and immunologically according to Mancini et al. ( 17 ) . Antithrombin III activity was measured by a chromogenic assay ( 18) , protein C activity by using synthetic substrate (Behringwerke, Marburg, FRG), and protein S by immunoassay (STAGO, Asnieres, France).
Protein purification. Fibrinogen was purified from plasma of the propositus and a normal individual ( 19) and further analyzed as described ( 12 ). Fibrinogen that lacked the carboxyl-terminal region was prepared as described (20 supernatant of thrombin-activated platelets by heparin-Sepharose affinity chromatography followed by Sepharose-4B gel filtration, essentially as described by Margossian et al. (21 ) and modified as described (22) . The calcium concentration was maintained at 2 mM throughout the purification procedure to avoid structural modification of the thrombospondin molecule. Purified thrombospondin was radiolabeled with carrier-free 1251I using the chloramine-T procedure to a specific activity of -0.2 MCi/Mg protein. The radiolabeled thrombospondin had the same electrophoretic mobility as the unlabeled counterpart, and exhibited specific and saturable binding to thrombin-activated platelets (22) . Protein concentrations were determined spectrophotometrically at 280 nrfi, the A ' used for fibrinogen and thrombospondin were 15.0 and 10.4, respectively.
Electron microscopic studies onfibrin. Fibrin for critical-point drying was prepared by addition of human a-thrombin (0.1 U/ml final concentration) to a solution of fibrinogen (50 ,g/ml in 50 mM Tris/ HCl, 100 mM NaCl, pH 7.4, buffer; ionic strength 0.14) followed by incubation for 60 min at room temperature. A specimen of the fibrin clot was picked up on a carbon-coated 200-mesh grid, fixed with glutaraldehyde/tannic acid, stained with uranyl acetate, dehydrated, and then critical-point dried. Electron microscopy (EM) was carried out in a model 400 electron microscope (Philips Electronic Instruments, Mahwah, NJ) at 120 kV.
Binding of thrombospondin to fibrinogen. Microtiter wells were coated in duplicate with 0.1 ml ofa 10 ,g/ml freshly prepared fibrinogen solution in 10 mM Tris/HCl, 150 mM NaCl, pH 7.4 (Tris buffer) containing 2 mM CaCl2, overnight at 22°C in a humid chamber. Wells were rinsed twice with Tris buffer containing 2 mM CaCl2, 1 mM MgCl2, and 0.05% (vol/vol) Tween 20 (Tris/Tween buffer), and subsequently incubated for 1 h with Tris/Tween buffer containing 1.5% (wt/vol) BSA. The wells were rinsed four times and incubated with increasing concentrations of 1251-thrombospondin in Tris/Tweenbuffer for 3 h. The wells were washed four times with Tris/Tween *buffer and cut out, and the radioactivity associated with each well was counted. Nonspecific binding was determined by measuring the binding of '251-thrombospondin to wells coated only with BSA.
Immunoblot analysis of plasma. SDS-PAGE was performed on 5-25% gradient gels according to Laemmli (23) or on 2-16% precast gradient gels (Pharmacia, Uppsala, Sweden) using an electrophoresis buffer containing 40 mM Tris, 20 mM sodium acetate, 2 mM disodium EDTA, 0.2% (wt/ vol) SDS, pH 7.4, and a sample buffer containing 10 mM Tris/HCl, 1 mM disodium EDTA, 1% (wt/vol) SDS, pH 8.0. Molecular mass was estimated using a low M, calibration kit (Pharmacia) containing proteins with an M, ranging from 14.4 to 94 kD or using a mixture of purified fibrinogen (340 kD), fibronectin (450 kD) (purified from fibrinogen by affinity chromatography on gelatin-Sepharose), and purified mouse monoclonal IgM (900 kD) (a generous gift from Dr. R. Bos, Gaubius Laboratory).
Proteins from the SDS-PAGE gels were electroblotted onto nitrocellulose (24) for 16 h at 400 mA and 10°C. The nitrocellulose sheets were blocked by incubating them in Tris/Tween buffer, pH 7.4, containing 0.15 M NaCl, 0.5% (wt/vol) gelatin for 2 h. After blocking, the blots were washed with Tris/Tween buffer and incubated for 2 h at room temperature with mouse monoclonal antifibrinogen Y18 (25) conjugated to horseradish peroxidase (HRP) diluted in Tris/Tween buffer (kindly provided by Dr. W. Nieuwenhuizen, Gaubius Laboratory). Identical blots were incubated for 2 h at room temperature with goat anti-human albumin conjugated to HRP (Nordic, Tilburg, The Netherlands) diluted in Tris/Tween buffer. The protein bands reacting with the different immunoconjugates were visualized by incubation with a substrate solution containing 4-chloro-1 -naphthol (26) .
DNA amplification and sequencing. Genomic DNA was isolated from blood cells as described (27) . Oligonucleotides were synthesized on a model 380A DNA synthesizer (Applied Biosystems, Inc., Foster City, CA). Oligonucleotides 1i2a(5'GCCTCTAAGGTTGTAGGA-ATTCTTCAG3') and #2b(5' ATCAGTGCACCCACCAAGTCT-GGG3') were used to amplify the B# gene segment coding for amino acids 9-72. Oligonucleotides a6a (5'GGCACGCTGGATGGG-TTC3') and a6b (5'GGACTTACAGTCGACCACAAAAACAGA-CC3') were used to amplify the part of the Aa-chain gene coding for amino acids 492-625 and a 12 l-bp nontranslated 3'sequence. Oligonucleotides ala (5TGTCTCCTCTTCTGGCTA3') and a2b (5'GTT-ATTGGCTGAGGAAAAATCGCC3') were used to amplify the Aa gene segment coding for amino acids 1-95. Oligonucleotides y4a (5'GAAGCATCCTACGAAAGAGGG3') and y4b (5'AACTTG-GAATCTAAGAAAGGAAAACTAACC3') and y5a (5'CTTCAT-AGACTTGCAGAG3') and y5b (5'AAGCAAGTCGACTGTCCA-ATAGGAAAAATA3') were used to amplify the y gene segment coding for amino acids 259-411. Amplification by PCR (14) was performed in a 100-Ml reaction volume containing I Ag of genomic DNA, 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Pharmacia), 0.2MM each ofprimera and bin lx reaction buffer((0mM Tris/HCl, pH 8.3, at 250C, 50 mM KCI, 3.0 mM MgCl2 and 0.001% [wt/vol] gelatin). The DNA was denatured at 940C for 4 min and 2.0 U Taq DNA polymerase (Perkin Elmer-Cetus, Norwalk, CT) was added. Cycles consisted of a 1-min at 94°C, 0.5-min at 58°C, and 1.5-min at 72°C incubation. After 30 cycles, the amplified DNA was precipitated with ethanol, dried, dissolved in 20 Ml of distilled water, and run on a 1.0% (wt/vol) ultra low gelling agarose gel (A-5030, Sigma Chemical Co., St. Louis, MO). The bands with the appropriate size, as predicted from the DNA sequence of the Aa ( I1), B# (28) , and y (29) chain genes were cut out ofthe gel in a volume of -20 Al and heated to 55°C. I Al of the melted agarose, containing -10 ng of DNA, was mixed with I Ml of the appropriate amplification primer (60 ng), and 2 Ml of 5X annealing buffer (T7 sequence kit, Pharmacia), the volume was brought up to 14 Ml with distilled water. The mixture was heated to 95°C for 3 min and immediately after this was put on ice, and labeling (5 min) and termination (10 min) reactions were performed using the T7 DNA sequence kit according to the manufacturer's instructions.
Detection of mutation in family members by restriction analysis. PCR samples containing the Aa fragment from the family members were incubated with the restriction endonuclease BSAJ I (New England Biolabs, Beverly, MA) according to the manufacturer's instructions. After incubation the restriction digests were analyzed on a 2% (wt/vol) agarose gel (A-6013, Sigma Chemical Co.) and stained with ethidium bromide. DNA molecular size markers were prepared by Rsa I (New England Biolabs) digestion of M13mpl8 DNA.
Results
Case report and laboratory data. The propositus (11.2 in Fig. 1) is a male Caucasian who developed spontaneous phlebitis at the age of 37 yr, which was treated by heparin followed by oral anticoagulant. At the age of41 yr, he suffered from pulmonary embolism and deep vein thrombosis ofthe left leg. The throm-I1 (Fig. 2) in the codon normally coding for arginine at position 554. This mutation changed the codon CGT (arginine) to TGT which codes for cysteine. The normal sequence was also present in Dusart 11.2, indicating that the propositus was heterozygous for this mutation.
Fibrin structure determined by electron microscopy. The fibrin fibers formed from fibrinogen Dusart at physiological pH and ionic strength were much thinner than the fibers present in normal fibrin (Fig. 3) , indicating impaired lateral association ofthe fibrin fibrils formed from fibrinogen Dusart. These results are consistent with previous observations that showed low turbidity of polymerized fibrin Dusart compared with normal fibrin ( 12) .
Binding of thrombospondin to fibrinogen. Thrombospondin binds to the carboxyl-terminal part of the fibrinogen Aaand Bf3-chain (30, 31 ) , and is thought to be an inhibitor of complex formation among fibrin, plasminogen, and t-PA (32) . As the mutation in fibrinogen Dusart is located in the carboxyl terminus of the Aa-chain, the binding of thrombospondin to immobilized fibrinogen Dusart was compared with binding to normal fibrinogen. 125I-thrombospondin bound to normal fibrinogen and fibrinogen Dusart in a concentration-dependent manner (Fig. 4) 3 ) of the propositus was not studied. However, one of them (II.3) showed a prolonged thrombin clotting time, indicating that he probably contained the molecular defect (see also Table I ). Immunoblot analysis ofplasma. To determine whether the additional cysteine created by the mutation in fibrinogen Dusart (Aa 554 Arg --Cys) is involved in disulfide-linked complex formation with other proteins (33) (34) (35) , plasma ofthe propositus, his siblings, and normal plasma was analyzed by immunoblotting after separation of plasma proteins on 2-16% gradient SDS-PAGE gels. The blots were incubated with a mouse monoclonal antifibrinogen antibody (Y18) and a goat 
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anti-human albumin antibody, both conjugated with HRP. After reaction with Y18 /HRP (Fig. 6 A) , normal plasma and the plasma of Dusart III.3 and 111.4 showed two intense bands with Me's of -340,000 and 300,000 D, corresponding to the high-and low-Me form of fibrinogen (36, 37) . Plasma of the four other family members ofDusart (I. 1, 11.2, 111. 1, and 111.2) contained the same two bands as normal plasma, and an additional intense band with a M, of 400,000 D. Several other faint bands were also present in the plasma ofthese individuals (1.2, II.2, 1.1, and III.2). After reaction with goat anti-human albumin/HRP (Fig. 6 B) normal plasma and plasma from Dusart 111.3 and III.4 showed no bands which reacted with this antibody. Plasma samples from Dusart 1. 1, 11.2, III. 1, and III.2 showed one intense band with an Mr of 400,000 D after reaction with the goat anti-human albumin/HRP conjugate. As indicated by the intense band with Mr 400,000 D, which reacted with antifibrinogen and antialbumin antibodies, the mutation in fibrinogen Dusart results in the formation ofcovalent complexes between the mutated fibrinogen and plasma albumin. Immunoblot analysis of reduced plasma samples with Y18/HRP (data not shown), did not show any high-Mr complex, indicating that the complex formation involves disulfide bridges between the different proteins.
In summary, the presence of the mutation in the Aa-chain of fibrinogen Dusart is accompanied by a prolonged thrombin clotting time and the presence ofdisulfide-linked fibrinogen-albumin complexes in plasma of the affected family members (Table I ).
Sulfhydryl content. To determine whether the cysteine residue at position Aa 554 in fibrinogen Dusart had been oxidized to disulfides, we evaluated the titratable sulfhydryl content using Ellman's reagent (38) . The analysis was performed in the presence of 8 M urea to denature the protein, because sulfhydryl groups can be present in native proteins in a nontitratable state (39) . Calculation ofthe number offree sulfhydryl groups showed that both normal fibrinogen and fibrinogen Dusart did not contain any detectable free sulfhydryl groups (<0.05 mol/mol).
Discussion
Using the polymerase chain reaction, we identified a singlebase substitution in the gene coding for the Aa sart is associated with abnormal fibrin polymerization ( 12) , reduced binding of Lys-plasminogen ( 12) , and defective t-PA induced plasminogen activation ( 1 3 Removal of the carboxyl-terminus from fibrinogen Dusart by limited plasmin digestion nearly normalized fibrin polymerization (20) , indicating that the remaining part of fibrinogen Dusart contained no mutation which could explain the impaired fibrin polymerization. Moreover, sequence analysis of amplified DNA coding for the terminal parts of fibrinogen, which are involved in fibrin polymerization, did not reveal any structural defect.
Previous reports on fibrinogen Dusart demonstrated that fibrin formed from it had a reduced binding of Lys-plasminogen ( 12) and a reduced accelerating effect on t-PA-induced plasminogen activation ( 13) . An explanation for these effects could be that Aa Arg 554 is part of a plasminogen binding site in normal fibrin, or that the presence of albumin, linked to Act Cys 554, masks this binding site in fibrin Dusart. However, thrombospondin, thought to bind to the carboxyl-terminal end of the fibrinogen Act chain (31 ) , bound normally to fibrinogen Dusart. Another explanation is that the functional defects related to fibrinolysis are the result ofthe impaired lateral association of fibrin fibrils in fibrin Dusart. The latter explanation is in agreement with the observation that inhibition of fibrin polymerization reduces the acceleratory effect of fibrin on t-PA-induced plasminogen activation (40) (41) (42) (43) . Further evidence for this hypothesis is presented by Mirshahi et al. (44) who showed that fibrin formed from low-Mr fibrinogen, which results in reduced lateral association (10) , is more resistant to fibrinolysis induced by t-PA than fibrin prepared from high-Mr fibrinogen.
Restriction analysis of the Aa gene fragments demonstrated that the three family members with a prolonged thrombin clotting time (. 1, III. 1, and 111.2) were also heterozygous for the defect, whereas the two family members with a normal thrombin clotting time (111.3 and 111.4) did not contain the mutated DNA sequence. From the family history of recurrent and massive thrombosis and the genetic analysis of the family members, the association of the clinical symptoms with the defect in fibrinogen Dusart is convincing. The mechanism responsible for the recurrent thrombosis in this family is most likely related to the decreased plasminogen binding to fibrin and the reduced acceleratory effect of fibrin on t-PA-induced plasminogen activation. This would indicate that the cofactor function of fibrin in regulating fibrinolysis is an important in vivo mechanism for inducing efficient thrombolysis and for preventing the occurrence of thrombosis.
